Scarica l'app Stockscreener
8.60
0.23%
-0.02
Dopo l'orario di chiusura:
9.09
0.49
+5.70%
Precedente Chiudi:
$8.62
Aprire:
$8.62
Volume 24 ore:
686.28K
Relative Volume:
0.80
Capitalizzazione di mercato:
$454.62M
Reddito:
$27.46M
Utile/perdita netta:
$-46.05M
Rapporto P/E:
-9.1489
EPS:
-0.94
Flusso di cassa netto:
$-33.83M
1 W Prestazione:
-4.02%
1M Prestazione:
+1.30%
6M Prestazione:
+81.82%
1 anno Prestazione:
+98.16%
Intervallo 1D:
$8.325
$8.69
Intervallo di 1 settimana:
$7.84
$9.21
Portata 52W:
$4.20
$9.21
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(321) 939-3416
Indirizzo
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Confronta ZVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ZVRA | 8.60 | 454.62M | 27.46M | -46.05M | -33.83M | -0.94 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
ZVRA FY2024 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance
Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News
Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St
Research Analysts Set Expectations for ZVRA FY2024 Earnings - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics (NASDAQ:ZVRA) Given New $23.00 Price Target at Canaccord Genuity Group - MarketBeat
Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Zevra Therapeutics’ Transformative Third Quarter 2024 - TipRanks
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Zevra Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Zevra Therapeutics earnings missed by $0.28, revenue fell short of estimates - Investing.com UK
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - The Manila Times
Zevra Therapeutics Validates Key Clinical Scale for Niemann-Pick Disease Treatment Study | ZVRA Stock News - StockTitan
Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Kn - GuruFocus.com
International Assets Investment Management LLC Raises Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ZVRA stock touches 52-week high at $8.96 amid market rally - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.83 Average PT from Analysts - MarketBeat
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - The Manila Times
Zevra Therapeutics CEO to Present at Guggenheim Healthcare Conference | ZVRA Stock News - StockTitan
Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance
How To Trade (ZVRA) - Stock Traders Daily
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Will Zevra Gallop Or Saunter In Q3? - RTTNews
Objective long/short (ZVRA) Report - Stock Traders Daily
Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India
Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $20.83 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 25.7% in September - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat
A company insider recently bought 2,000 shares of Zevra Therapeutics Inc [ZVRA]. Should You Buy? - Knox Daily
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented - EIN News
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zevra Therapeutics Inc Azioni (ZVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Clifton R. LaDuane | CFO & Treasurer |
Jul 17 '24 |
Buy |
6.77 |
2,000 |
13,540 |
18,469 |
| Anderson Thomas | Director |
Jul 16 '24 |
Buy |
6.81 |
10,000 |
68,065 |
20,000 |
| Bode John B | Director |
Jul 12 '24 |
Buy |
5.87 |
10,000 |
58,661 |
30,000 |
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):